Table 3.

Summary table of meta-analysis results of prevalence of sarcopenia in the older adult in China.

Subgroup	Number of included literature	Results of heterogeneity test		Effect model	The prevalence % (95%Cl)
		I2	p
Total prevalence rate (24–68)	45	99.2%	<0.001	Random effect model	20.7 (18.3, 23.0)
Sex
Men (24, 25, 27, 29–33, 35, 37–41, 43–45, 47, 48, 50, 51, 54–64, 66, 67)	34	94.7%	<0.001	Random effect model	19.2 (16.6, 21.8)
Women (24, 25, 27, 29–33, 35, 37–41, 43–45, 47, 48, 50, 51, 54–64, 66, 67)	34	96.5%	<0.001	Random effect model	21.6 (18.7, 24.5)
Age
60–69 (26, 27, 31–33, 35, 41, 48, 64, 65)	10	96.0%	<0.001	Random effect model	15.7 (10.6, 20.7)
70–79 (26, 27, 31–33, 35, 41, 48, 64, 65)	10	95.4%	<0.001	Random effect model	27.2 (20.2, 34.3)
≥80 (26, 27, 31–33, 35, 41, 48, 64, 65)	10	88.8%	<0.001	Random effect model	45.4 (35.9, 54.9)
Region
South (24, 29, 31, 32, 36–39, 41, 44, 45, 50–52, 54–62, 65–68)	27	97.7%	<0.001	Random effect model	21.7 (18.5, 24.9)
North (26, 28, 30, 33–35, 40, 43, 46–49, 53, 63, 64)	15	97.6%	<0.001	Random effect model	19.0 (14.9, 23.1)
Publication year
2014–2018 (54–68)	15	97.3%	<0.001	Random effect model	19.2 (15.8, 22.7)
2019–2024 (24–53)	30	97.6%	<0.001	Random effect model	21.4 (18.4, 24.3)
Diagnostic criteria
AWGS (2019) (24–32, 36, 38, 39, 41)	13	97.6%	<0.001	Random effect model	24.5 (20.3, 28.7)
AWGS (2014) (37, 40, 43, 45–47, 49, 50, 52, 53, 57, 59, 60, 62–64)	16	96.4%	<0.001	Random effect model	19.3 (15.5, 23.1)